OIPE

#3

RAW SEQUENCE LISTING   DATE: 11/21/2001
PATENT APPLICATION: US/09/813,271   TIME: 12:21:05

Input Set : N:\Crf3\RULE60\09813271.txt
Output Set: N:\CRF3\11212001\I813271.raw

SEQUENCE LISTING
```
 3 (1) GENERAL INFORMATION:
 5      (i) APPLICANT: Arvinte, Tudor.
 7     (ii) TITLE OF INVENTION: Pharmaceutical Compositions
 9    (iii) NUMBER OF SEQUENCES: 5
11     (iv) CORRESPONDENCE ADDRESS:
12          (A) ADDRESSEE: NOVARTIS Corporation
13          (B) STREET: 564 Morris Avenue
14          (C) CITY: Summit
15          (D) STATE: New Jersey
16          (E) COUNTRY: USA
17          (F) ZIP: 07901-1027
19      (v) COMPUTER READABLE FORM:
20          (A) MEDIUM TYPE: Floppy disk
21          (B) COMPUTER: IBM PC compatible
22          (C) OPERATING SYSTEM: PC-DOS/MS-DOS
23          (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
25     (vi) CURRENT APPLICATION DATA:
```
C--> 26   **(A) APPLICATION NUMBER: US/09/813,271**
C--> 27   **(B) FILING DATE: 20-Mar-2001**
```
28          (C) CLASSIFICATION:
34    (vii) PRIOR APPLICATION DATA:
31          (A) APPLICATION NUMBER: 09/303,970
32          (B) FILING DATE:
35          (A) APPLICATION NUMBER: GB 9401447.9
36          (B) FILING DATE: 26-JAN-1994
38   (viii) ATTORNEY/AGENT INFORMATION:
39          (A) NAME: Pfeiffer, Hesna J.
40          (B) REGISTRATION NUMBER: 22,640
41          (C) REFERENCE/DOCKET NUMBER: 4-18518/A/MA
43     (ix) TELECOMMUNICATION INFORMATION:
44          (A) TELEPHONE: (908)522 6940
45          (B) TELEFAX: (908)522 6955
54 (2) INFORMATION FOR SEQ ID NO: 1:
55      (i) SEQUENCE CHARACTERISTICS:
57          (A) LENGTH: 65 amino acids
58          (B) TYPE: amino acid
59          (C) STRANDEDNESS: single
60          (D) TOPOLOGY: linear
62     (ii) MOLECULE TYPE: protein
64    (iii) HYPOTHETICAL: no
66     (iv) ANTI-SENSE: no
68     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
70 Val Val Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys Leu Cys
71 1               5                  10                  15
```
W--> 73 Glu Gly Ser Asn Val Cys Gly Gln Gly Asn Xaa Cys Ile Leu Gly Ser
```
74               20                  25                  30
```

ENTERED

RAW SEQUENCE LISTING   DATE: 11/21/2001
PATENT APPLICATION: US/09/813,271   TIME: 12:21:05

Input Set : N:\Crf3\RULE60\09813271.txt
Output Set: N:\CRF3\11212001\I813271.raw

```
W--> 76 Asp Gly Glu Xaa Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Xaa Pro
     77         35                  40                  45
W--> 79 Gln Ser Xaa Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Xaa Xaa Xaa Xaa
     80         50                  55                  60                  65
     83 (2) INFORMATION FOR SEQ ID NO: 2:
     85       (i) SEQUENCE CHARACTERISTICS:
     87             (A) LENGTH: 65 amino acids
     88             (B) TYPE: amino acid
     89             (C) STRANDEDNESS: single
     90             (D) TOPOLOGY: linear
     92      (ii) MOLECULE TYPE: protein
     93     (iii) HYPOTHETICAL: no
     94      (iv) ANTI-SENSE: no
     96      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
     98 Leu Thr Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys Leu Cys
     99 1             5                  10                  15
    101 Glu Gly Ser Asn Val Cys Gly Gln Gly Asn Lys Cys Ile Leu Gly Ser
    102         20                  25                  30
    104 Asp Gly Glu Lys Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Lys Pro
    105         35                  40                  45
    107 Gln Ser His Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu
    108         50                  55                  60
    110 Gln
    111 65
    113 (2) INFORMATION FOR SEQ ID NO: 3:
    115       (i) SEQUENCE CHARACTERISTICS:
    117             (A) LENGTH: 65 amino acids
    118             (B) TYPE: amino acid
    119             (C) STRANDEDNESS: single
    120             (D) TOPOLOGY: linear
    122      (ii) MOLECULE TYPE: protein
    123     (iii) HYPOTHETICAL: no
    124      (iv) ANTI-SENSE: no
    126      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
    128 Ile Thr Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys Leu Cys
    129 1             5                  10                  15
    131 Glu Gly Ser Asn Val Cys Gly Lys Gly Asn Lys Cys Ile Leu Gly Ser
    132         20                  25                  30
W--> 134 Asn Gly Lys Gly Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Xaa Pro
    135         35                  40                  45
W--> 137 Glu Ser His Asn Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Xaa Leu
    138         50                  55                  60
    140 Gln
    141 65
    144 (2) INFORMATION FOR SEQ ID NO: 4:
    146       (i) SEQUENCE CHARACTERISTICS:
    148             (A) LENGTH: 65 amino acids
    149             (B) TYPE: amino acid
    150             (C) STRANDEDNESS: single
```

```
151              (D) TOPOLOGY: linear
153      (ii) MOLECULE TYPE: protein
154     (iii) HYPOTHETICAL: no
155      (iv) ANTI-SENSE: no
157      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
159 Val Val Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys Leu Cys
160 1               5                  10                  15
162 Glu Gly Ser Asn Val Cys Gly Lys Gly Asn Lys Cys Ile Leu Gly Ser
163             20                  25                  30
165 Asn Gly Lys Gly Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Asn Pro
166         35                  40                  45
168 Glu Ser His Asn Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu
169     50                  55                  60
172 Gln
173 65
176 (2)  INFORMATION FOR SEQ ID NO: 5:
178      (i) SEQUENCE CHARACTERISTICS:
180             (A) LENGTH: 66 amino acids
181             (B) TYPE: amino acid
182             (C) STRANDEDNESS: single
183             (D) TOPOLOGY: linear
185      (ii) MOLECULE TYPE: protein
186     (iii) HYPOTHETICAL: no
187      (iv) ANTI-SENSE: no
190      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
193 Ile Thr Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys Leu Cys
194 1               5                  10                  15
196 Glu Gly Ser Asn Val Cys Gly Lys Gly Asn Lys Cys Ile Leu Gly Ser
197             20                  25                  30
199 Gln Gly Lys Asp Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Lys Pro
200         35                  40                  45
202 Gln Ser His Asn Gln Gly Asp Phe Glu Pro Ile Pro Glu Asp Ala Tyr
203     50                  55                  60
205 Asp Glu
206 65
```

VERIFICATION SUMMARY   DATE: 11/21/2001
PATENT APPLICATION: **US/09/813,271**   TIME: 12:21:06

Input Set : **N:\Crf3\RULE60\09813271.txt**
Output Set: **N:\CRF3\11212001\I813271.raw**

L:26 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:]
L:27 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:]
L:73 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:76 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:79 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:134 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:137 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3